Skip to content

Simulated Clinical Use Testing on Safety Lancets (Test A)

Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test A)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03807635
Enrollment
20
Registered
2019-01-17
Start date
2018-11-30
Completion date
2018-12-13
Last updated
2019-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Needle Stick

Keywords

needlestick, needlestick injury, safety lancet, sharps injury prevention, capillary blood sampling

Brief summary

A simulated clinical use testing on the HTL-Strefa's safety lancets

Detailed description

This study aims to evaluate the safety of the use of the safety lancets: ergoLance and Acti-Lance in the prevention of NSI and to evaluate the user's opinion with regards to the handling characteristics of the medical devices. The simulated use clinical study will involve healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples and lay persons.

Interventions

DEVICEergoLance safety lancet

The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.

DEVICEActi-Lance safety lancet

The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.

Sponsors

HTL-Strefa S.A.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

The inclusion criteria for HCP and lay person evaluators have been chosen based on FDA guidance: * (HCP evaluators only) - evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts) * evaluators will be United States (US) residents * evaluators can read, write, and speak English * evaluators are at least 18 years old * evaluators are able to understand and provide signed consent for the study * evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires. * evaluators have no concerns about the ability to perform the simulated skin pricking. Lay person evaluators will have a diverse range of ages (18+ years), socioeconomic statuses, and race/ethnic backgrounds. UL-Wiklund will recruit some lay person evaluators with reduced vision and dexterity. Users without safety lancet experience may also be included in this simulated clinical use study.

Exclusion criteria

HCPs: * They do not routinely use safety lancets to collect capillary blood samples, * They cannot read, write, and speak English, * They or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or * They have participated in a product evaluation or marketing study involving safety lancets within the last six months Lay people: * They cannot read, write, and speak English, * They or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or * They have participated in a product evaluation or marketing study involving safety lancets within the last six months

Design outcomes

Primary

MeasureTime frameDescription
The true failure rate of the tested devicesAt time of testing, up to 90 minutes
Effectiveness of the safety lancet's sharps injury prevention featuresAt time of testing, up to 90 minutesEvaluator questionnaire using five-point response Likert scale (coded from 1 strongly disagree to 5 strongly agree) to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a greater than relationship.

Secondary

MeasureTime frameDescription
Safety of the devices based on the evaluators' assessments (five-point response scale)At time of testing, up to 90 minutesEvaluator questionnaire using five-point response Likert scale (coded from 1 strongly disagree to 5 strongly agree) to measure any and all observed needlestick injuries and device malfunctions. Numbers assigned to Likert scale express a greater than relationship.
Subjective assessments regarding evaluators' interactions with the tested safety lancetsAt time of testing, up to 90 minutesEvaluator questionnaire using five-point response Likert scale (coded from 1 strongly disagree to 5 strongly agree) to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a greater than relationship.
Various aspects of the ease of use.At time of testing, up to 90 minutesEvaluator questionnaire using five-point response Likert scale (coded from 1 strongly disagree to 5 strongly agree) to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a greater than relationship.
Any handling, usability questions / issues associated with the deviceAt time of testing, up to 90 minutesEvaluator questionnaire using five-point response Likert scale (coded from 1 strongly disagree to 5 strongly agree) to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a greater than relationship.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026